Misplaced Pages

Ruboxistaurin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 17:10, 30 May 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 17:10, 30 May 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ()(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Ruboxistaurin
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • (9S)-9--6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzopyrrolooxadiazacyclohexadecine-18,20-dione
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28N4O3
Molar mass468.546 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C6NC(=O)C=5c1cn(c2ccccc12)CCO(CN(C)C)CCn4c3ccccc3c(c4)C=56
InChI
  • InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
  • Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N
  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is currently being investigated by Eli Lilly and Company.

On February, 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.

References

  1. "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
  2. "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
  3. Clarke M, Dodson PM (2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736. {{cite journal}}: Unknown parameter |month= ignored (help)

External links

Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: